Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript

Core Insights - Natera has experienced remarkable growth in its Signatera product over the past few years, with over 100 publications supporting its clinical evidence [1] - The company has acquired technology for PhasED variance, which enhances sensitivity in its diagnostics [1] - Natera's women's health business is performing well, holding over 40% market share in non-invasive prenatal testing (NIPT) [1] - Despite increasing competition, Natera is proactively addressing challenges in the market [1]